Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab continuation protocol for prior Novartis study completers
2023-504417-67-00Phase 4Authorised
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 4, open-label, single-arm trial of secukinumab in psoriatic arthritis (PsA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA) and 2 more, sponsored by Novartis. Primary endpoints: Serious adverse events, Adverse events and 1 more. Planned start Dec 2020; status: authorised.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)psoriasisjuvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2023-504417-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504417-67-00.